Jeffrey T. Czaplinski

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

César Serrano, Adrián Mariño‐Enríquez, Derrick L. Tao et al. · British Journal of Cancer · 2019 · 159 citations · Full text

Antiproliferative Effects of CDK4/6 Inhibition in <i>CDK4</i> -Amplified Human Liposarcoma <i>In Vitro</i> and <i>In Vivo</i>

Yi-Xiang Zhang, Ewa Sicińska, Jeffrey T. Czaplinski et al. · Molecular Cancer Therapeutics · 2014 · 111 citations

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

Robert Nakayama, Yi-Xiang Zhang, Jeffrey T. Czaplinski et al. · Oncotarget · 2016 · 71 citations · Full text

Oncogenic Agent, Preclinical Activity, Sarcoma Models +13

<i>CDKN2A</i>/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans

Grant Eilers, Jeffrey T. Czaplinski, Mark Mayeda et al. · Molecular Cancer Therapeutics · 2015 · 51 citations · Full text

Imatinib-resistant Dermatofibrosarcoma Protuberans, Dfsp Progression, Dfsp Progress +15

c‐Jun promotes cell migration and drives expression of the motility factor <scp>ENPP2</scp> in soft tissue sarcomas

Stefano Sioletic, Jeffrey T. Czaplinski, Lan Hu et al. · The Journal of Pathology · 2014 · 37 citations

C‐jun Promotes, Immunology, Immunoediting +20